Form 8-K - Current report:
SEC Accession No. 0001213900-24-077411
Filing Date
2024-09-10
Accepted
2024-09-10 17:01:00
Documents
18
Period of Report
2024-09-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ea021395101-8k_emmaus.htm   iXBRL 8-K 30778
2 SEPTEMBER 10, 2024 LETTER OF BAKER TILLY US, LLP TO THE SECURITIES AND EXCHANGE ea021395101ex16-1_emmaus.htm EX-16.1 4394
3 SEPTEMBER 10, 2024 PRESS RELEASE ea021395101ex99-1_emmaus.htm EX-99.1 41277
4 GRAPHIC image_001.jpg GRAPHIC 8580
5 GRAPHIC ex16-1_001.jpg GRAPHIC 23893
6 GRAPHIC ex16-1_002.jpg GRAPHIC 26877
  Complete submission text file 0001213900-24-077411.txt   337347

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE emma-20240905.xsd EX-101.SCH 3009
8 XBRL LABEL FILE emma-20240905_lab.xml EX-101.LAB 34240
9 XBRL PRESENTATION FILE emma-20240905_pre.xml EX-101.PRE 22355
20 EXTRACTED XBRL INSTANCE DOCUMENT ea021395101-8k_emmaus_htm.xml XML 3359
Mailing Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503
Business Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503 310-214-0065
Emmaus Life Sciences, Inc. (Filer) CIK: 0000822370 (see all company filings)

EIN.: 870419387 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35527 | Film No.: 241290711
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)